The disclosure of a significant passive stake by a prominent investment firm like RA Capital Management often signals a vote of confidence to the market, potentially leading to a positive short-term impact on the stock price of C4 Therapeutics. Investors may interpret this stake as a sign of long-term growth potential or undervaluation. However, as the stake is passive, it does not indicate an intention to influence or control the company's management.